CAI vs PATH · rev $216.8M vs P/E 19, rev $1.61B
Caris Life Sciences, Inc. Common Stock (CAI) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CAI revenue for 2025-09-30 was $216.8M. Net income was $24.3M. Revenue was up 19.5% from 2025-06-30 to 2025-09-30. CAI currently screens at market cap $5.22B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CAI currently screens at market cap $5.22B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CAI and PATH stock pages for the full models.
Not investment advice.